Turning Point Therapeutics is Biotechnology in United States that focus on Point Therapeutics Inc business. Founded in 2013. They cover business area such as Turning Point Therapeutics Inc, molecule, oncology therapy, limitation, exist therapy, a pipeline, next-generation tyrosine kinase inhibitor, TKIs, genetic driver, cancer, TKI-pretreate patient, repotrectinib, NSCLC, alk+, solid tumor.
2013
( 11 years old in 2024 )
Point Therapeutics Inc
-
10628 Science Center Drive
Suite 225
San Diego, CA 92121
United States
Private
Turning Point Therapeutics Incmoleculeoncology therapylimitationexist therapya pipelinenext-generation tyrosine kinase inhibitorTKIsgenetic drivercancerTKI-pretreate patientrepotrectinibNSCLCalk+solid tumor
* We use standard office opening hours in near Turning Point Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Turning Point Therapeutics is Biotechnology business from United States that founded in 2013 (11 years old in 2024), Turning Point Therapeutics business is focusing on Point Therapeutics Inc.
Turning Point Therapeutics headquarter office and corporate office address is located in 10628 Science Center Drive Suite 225 San Diego, CA 92121 United States.
Turning Point Therapeutics was founded in United States.
In 2024, Turning Point Therapeutics is currently focus on Point Therapeutics Inc sector.
Above is snippet of Google Trends for "Point Therapeutics Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Turning Point Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
